Cantargia reports start of multiple dosing part in CAN10 phase 1 clinical trial
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that the first participant has started study treatment in the second part of the phase 1 clinical trial using CAN10, an antibody designed for treatment of autoimmune or inflammatory diseases. This part investigates multiple dosing during 6 weeks in participants with mild to moderate plaque psoriasis. Besides safety and pharmacokinetics, the trial is designed to analyze a number of biomarkers in both skin biopsies as well as blood.
“The CAN10 clinical program continues to advance nicely with the start of multiple dosing. As this part of the phase 1 trial evaluates participants with psoriasis, significant data will be generated which will be useful to investigate the CAN10 mechanism of action and disease biomarkers in patients ahead of larger phase 2 studies,” said Göran Forsberg, CEO of Cantargia.
CAN10 is one of two clinical projects in the Cantargia pipeline. The CAN10 antibody has been designed for treatment of several autoimmune/inflammatory diseases. The ongoing phase 1 clinical trial initially investigates increasing levels of CAN10 as single dose administration in healthy subjects followed by studies of multiple dosing using subcutaneous administration in participants with psoriasis. The primary endpoint relates to safety. Details on the trial can be found at https://clinicaltrials.gov/study/NCT06143371.
No safety concerns have been observed during the single dose studies to date and in accordance with the protocol, the first of two planned multiple dosing groups has now started. Each participant will receive treatment during six weeks and treatment in the two groups are planned to finish end of Q1 2025.